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Abstract
Objective: Dietary carbohydrate is the major determinant of postprandial glucose levels, and
several clinical studies have shown that low-carbohydrate diets improve glycemic control. In this
study, we tested the hypothesis that a diet lower in carbohydrate would lead to greater
improvement in glycemic control over a 24-week period in patients with obesity and type 2
diabetes mellitus.
Research design and methods: Eighty-four community volunteers with obesity and type 2
diabetes were randomized to either a low-carbohydrate, ketogenic diet (<20 g of carbohydrate
daily; LCKD) or a low-glycemic, reduced-calorie diet (500 kcal/day deficit from weight maintenance
diet; LGID). Both groups received group meetings, nutritional supplementation, and an exercise
recommendation. The main outcome was glycemic control, measured by hemoglobin A1c.
Results:  Forty-nine (58.3%) participants completed the study. Both interventions led to
improvements in hemoglobin A1c, fasting glucose, fasting insulin, and weight loss. The LCKD group
had greater improvements in hemoglobin A1c (-1.5% vs. -0.5%, p = 0.03), body weight (-11.1 kg vs.
-6.9 kg, p = 0.008), and high density lipoprotein cholesterol (+5.6 mg/dL vs. 0 mg/dL, p < 0.001)
compared to the LGID group. Diabetes medications were reduced or eliminated in 95.2% of LCKD
vs. 62% of LGID participants (p < 0.01).
Conclusion:  Dietary modification led to improvements in glycemic control and medication
reduction/elimination in motivated volunteers with type 2 diabetes. The diet lower in carbohydrate
led to greater improvements in glycemic control, and more frequent medication reduction/
elimination than the low glycemic index diet. Lifestyle modification using low carbohydrate
interventions is effective for improving and reversing type 2 diabetes.
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Background
The dietary macronutrient that raises postprandial serum
glucose and insulin most potently is carbohydrate [1].
This observation led to the use of diets low in carbohy-
drate for the treatment of diabetes before insulin or other
medication therapies were available [2]. In like fashion,
individuals who are insulin-deficient are instructed to
estimate the amount of carbohydrate in the meal and then
to administer the insulin dosage based upon the amount
of dietary carbohydrate. This strong relationship between
dietary carbohydrate and postprandial serum glucose led
to the development of medications that block carbohy-
drate absorption for the treatment of type 2 diabetes [3].
Clinical studies that have lowered the percentage of die-
tary carbohydrate and/or the glycemic index of the carbo-
hydrate have consistently shown improvements in
glycemic control among individuals with type 2 diabetes
[4-8]. In randomized studies, low-carbohydrate diets have
been found effective for the treatment of obesity for dura-
tions up to 24 months [9]. While glycemic control was not
a primary outcome, some of these studies additionally
demonstrated improvement in glycemic parameters when
carbohydrate intake was lowered. In the Nurse's Health
Study cohort study, low-glycemic load diets were found to
be associated with lower cardiac risk over a 20 year period
[10]. One mechanism to explain these findings is that
when patients are instructed to limit carbohydrate intake
to low levels without mention of caloric intake, there is an
overall reduction in caloric intake [11].
In several recent studies, in the outpatient setting and met-
abolic ward, low-carbohydrate ketogenic diets led to
improvements in glycemic control among patients with
diabetes [12-16]. While it may be intuitive that a low-car-
bohydrate ketogenic diet with fewer than 20 grams of car-
bohydrate intake per day would lead to better glycemic
control than a "low-glycemic diet", we are not aware that
this idea has been actually tested. In the present study, our
hypothesis was that a diet lower in carbohydrate would
lead to greater improvement in glycemic control in
patients with obesity and type 2 diabetes mellitus over 24
weeks in the outpatient setting.
Methods
Participants
Participants were recruited from the community by news-
paper advertisements. After telephone screening, poten-
tial participants were scheduled for a "screening visit"
which included informed consent approved by the local
institutional review board, a medical history, physical
examination and laboratory tests. The inclusion criteria
were: diagnosis of type 2 diabetes mellitus > 1 year (con-
firmed by hemoglobin A1c > 6.0%), onset of diabetes after
age 15 years, no history of diabetic ketoacidosis, age 18–
65 years old, body mass index (BMI) from 27–50 kg/m2,
and desire to lose weight. Exclusion criteria were: unstable
or serious medical condition; significant co-morbid ill-
nesses such as liver disease (AST or ALT > 100 IU/L), kid-
ney disease (serum creatinine > 1.5 mg/dL), cancer;
pregnancy; or nursing mothers. No monetary incentives
were given.
Interventions
If study criteria were met, participants were randomized to
one of two treatment groups stratified upon BMI greater
or less than 32 kg/m2 using a computer-generated list, and
invited to attend the "baseline visit." (Measurements
taken at the "screening visit" were used as the initial value
in comparison testing for laboratory tests; measurements
from the "baseline visit" were used as the initial value for
other outcomes.) The intervention for both groups
included group sessions, diet instruction, nutritional sup-
plements, and an exercise recommendation. Group meet-
ings took place at an outpatient research clinic every week
for 3 months, then every other week for 3 months. If a par-
ticipant was taking medication for diabetes or hyperten-
sion, a physician reviewed the blood glucose and blood
pressure readings and made medication changes accord-
ing to a pre-specified algorithm. Participants were encour-
aged to exercise for 30 minutes at least 3 times per week,
but no formal exercise program was provided. Both
groups received the same nutritional supplements known
to have a mild lowering effect on blood glucose levels
(vanadyl sulfate 200 mcg/day, chromium dicotinate glyci-
nate 600 mcg/day, alpha-lipoic acid 200 mg/day) [17,18].
Low-carbohydrate, Ketogenic Diet Group Intervention (LCKD)
Using a lay-press diet book and additional handouts, a
registered dietitian instructed participants to restrict
intake of dietary carbohydrate to fewer than 20 grams per
day, without explicitly restricting caloric intake [19].
Allowed foods were unlimited amounts of animal foods
(i.e., meat, chicken, turkey, other fowl, fish, shellfish) and
eggs; limited amounts of hard cheese (e.g., cheddar or
swiss, 4 ounces per day), fresh cheese (e.g., cottage or
ricotta, 2 ounces per day), salad vegetables (2 cupfuls per
day), and non-starchy vegetables (1 cupful per day). Par-
ticipants were encouraged to drink at least 6 glasses of per-
mitted fluids daily. Drinking bouillon dissolved in water
was recommended 2–3 times a day during the first two
weeks to reduce possible side effects.
Low-glycemic index diet group intervention (LGID)
Using a lay-press diet book and additional handouts, a
registered dietitian instructed participants to follow a low-
glycemic index, reduced-calorie diet with approximately
55% of daily caloric intake from carbohydrate [20]. The
energy intake was individualized to be 2.1 MJ (500 kcal)
less than the participant's calculated energy intake forNutrition & Metabolism 2008, 5:36 http://www.nutritionandmetabolism.com/content/5/1/36
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weight maintenance (21.6*lean body mass + 370 kcal +
activity factor) [21].
Primary outcome measure
Hemoglobin A1c
Hemoglobin A1c was measured at baseline, week 12, and
week 24. The primary outcome was change in hemo-
globin A1c from baseline to week 24, using an immu-
noassay technique. The hemoglobin A1c  provides an
estimate of glycemic control for the previous 3-month
period and is predictive of clinical outcomes [22].
Other outcome measures
Diet composition
All participants completed food records (5 consecutive
days, including a weekend) at baseline, and during the
intervention (weeks 4, 12, and 24). Participants were
instructed how to document food record information and
given handouts with examples of how to complete the
records. A sample of completers (n = 8 for low-carbohy-
drate diet group; n = 7 for low-glycemic diet group) was
selected for food record analysis based upon record detail.
A registered dietitian analyzed the food records using a
nutrition software program (Nutritionist Five, Version
1.6, First DataBank Inc., San Bruno, CA). Food record
results were averaged over weeks 4, 12, and 24.
Vital signs
Wearing light clothing and no shoes, participants were
weighed at each visit on the same calibrated scale. Body
mass index was calculated as: (body weight in kilograms)/
(height in meters)2. Systolic and diastolic blood pressures
were measured in the non-dominant arm using an auto-
mated digital cuff (model HEM-725C, Omron Corp., Ver-
non Hills, IL) after sitting for 3 minutes. Two
measurements were taken per visit and averaged for the
analysis.
Other metabolic effects
Blood tests were obtained in the morning after at least 8
hours of fasting and processed by a commercial labora-
tory (Labcorp, Burlington NC). Glomerular filtration rate
was estimated by using an equation containing the varia-
bles age, gender, race, and serum albumin, creatinine, and
blood urea nitrogen (Modification of Diet in Renal Dis-
ease (MDRD) Study equation) [23]. Twenty-four hour
urine collections for protein were collected at baseline and
at 24 weeks.
Adverse effects
At all return visits, participants completed an open-ended
side effects questionnaire. To enhance the description of
side effects, participants completed a checklist of side
effects commonly mentioned during weight loss studies at
both the 20 and 24-week visit. These two measures were
combined to report the proportion in each group who
experienced an adverse effect at any time during the study.
Medication changes
At baseline and at all return visits, participants recorded
all of their current medications with dosages and sched-
ules.
Adherence
Adherence with the diet and exercise recommendations
was measured by self-report, food records, and urinary
ketones [24,25]. The delivery of the intervention and the
assessment of outcomes were not blinded to the treatment
assignment.
Statistical analysis
For categorical outcomes, comparisons between groups
were performed using the chi square test or Fisher's exact
test, as appropriate. For all continuous outcomes, compar-
isons were made using a t-test or Wilcoxon rank-sum test
as appropriate, testing the difference between groups for
the change from baseline to week 24. For the primary out-
come variable, a completer's analysis and last observation
carried forward (LOCF) were performed, and a multiple
linear regression analysis adjusting for weight change was
performed to determine if the change in hemoglobin A1c
was independent of weight loss. A p value of ≤ 0.05 was
considered statistically significant. Analyses were per-
formed using SAS Statistical Software, Version 8.02 (SAS
Institute Inc., Cary, NC). In order to detect a clinically
meaningful change in hemoglobin A1c (absolute change
of 1%, SD = 1.5) with 80% power (two-sided alpha of .05)
in a completers analysis, a total of 60 participants was
required. To protect for dropouts, 97 participants were
recruited.
Role of the funding source
The investigators conducted the study independently of
the funding source. The funding source had no involve-
ment in conduct of the study.
Results
Participants
213 potential participants were screened for eligibility,
and 97 were randomized. Ten participants of 48 rand-
omized to the LCKD group, and 3 of 49 participants ran-
domized to the LGID group discontinued the study prior
to the Week 0 visit and did not receive instruction, leaving
38 in the LCKD group and 46 in the LGID group for the
analyses. For the LCKD group, 21 (55.3%) completed the
study; reasons for discontinuation were: 3 refused
assigned diet, 2 were unsatisfied with the diet, 2 were lost
to follow-up, 2 were too busy, 1 relocated, and 7 cited no
reason. For the LGID group 29 (63.0%) completed the
study; reasons for discontinuation were: 1 refusedNutrition & Metabolism 2008, 5:36 http://www.nutritionandmetabolism.com/content/5/1/36
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assigned diet, 1 was unsatisfied with the diet, 2 were lost
to follow-up, 3 were too busy, 1 relocated, 1 had difficulty
adhering to the diet and 9 cited no reason. The baseline
characteristics of study participants are shown in Table 1.
There were no clinically significant differences between
the treatment groups.
Hemoglobin A1c
From baseline to 24 weeks, the reduction of mean ± SD
hemoglobin A1c was greater for the LCKD group (8.8 ±
1.8% to 7.3 ± 1.5%, p = 0.009, within group change, n =
21) than for the LGID group (8.3 ± 1.9% to 7.8 ± 2.1% p
= NS, within group change, n = 29; between groups com-
parison p = 0.03) (Table 2). The mean change in hemo-
globin A1c for the LCKD group was -1.5% (95% CI: -2.30,
-0.71), and for the LGID group was -0.5% (95%CI: -1.04,
0.10). Using a theoretical probability matrix comparing
the change in hemoglobin A1c for each individual in one
group to each individual in the other group, the probabil-
ity of having a greater improvement in hemoglobin A1c
was 0.683 for being assigned to the LCKD group, com-
pared to 0.300 for being in the LGID group (Figure 1)
[26]. Fasting blood glucose and insulin improved simi-
larly for both groups over the 24 weeks. In the LOCF anal-
ysis, the mean hemoglobin A1c at baseline and week 24
was 8.5% and 7.5% for the LCKD group, and 8.3% and
8.0% for the LGID group (p = 0.02, between groups com-
parison). In a multivariate linear regression model adjust-
ing for weight change or BMI change, the between group
comparison in change in hemoglobin A1c approached sta-
tistical significance (p = 0.06). Additionally, there was no
correlation between change in hemoglobin A1c  and
change in weight (Figure 2).
Medication changes
At baseline, 22 (75.9%) of the LGID group were taking
hypoglycemic medications (insulin only n = 3, oral agents
only n = 19), and 20 (95.2%) of the LCKD group were tak-
ing hypoglycemic medications (insulin + oral agents n =
4, insulin only n = 4, oral agents only n = 12). Twenty of
21 (95.2%) LCKD group participants had an elimination
or reduction in medication, compared with 18 of 29
(62.1%) LGID group participants (p < 0.01). Table 3
shows the changes in medication for those patients who
were taking insulin at baseline. Five individuals (4 in the
LCKD group, 1 in the LGID group) who were taking over
20 units of insulin at baseline were no longer taking insu-
lin at the end of the study.
Adherence
Prior to the study intervention, the mean ± SD dietary
intake for both groups was 2128 ± 993 kcal, 245 ± 136 g
of carbohydrate (46% of daily energy intake), 86 ± 33 g of
protein (18% of daily energy intake), 88 ± 57 g of fat
(36% of daily energy intake). Over the 24-week duration
of the intervention, the LCKD group consumed 1550 ±
440 kcal per day, 49 ± 33 g of carbohydrate (13% of daily
energy intake), 108 ± 33 g of protein (28% of daily energy
intake), 101 ± 35 g of fat (59% of daily energy intake). In
comparison, the LGID group consumed 1335 ± 372 kcal
per day, 149 ± 46 g of carbohydrate (44% of daily energy
intake), 67 ± 20 g of protein (20% of daily energy intake),
55 ± 23 g of fat (36% of daily energy intake). There was no
difference in self-reported exercise between the groups:
the mean number of exercise sessions per week increased
from 2.0 ± 2.0 to 3.0 ± 2.0 for the LCKD group and from
2.2 ± 2.2 to 3.8 ± 2.9 for the LGID group (p = 0.39 for
comparison).
Vital signs
There was significantly greater weight loss for the LCKD
than the LGID group over the 24 weeks: body weight
decreased from 108.4 ± 20.5 kg to 97.3 ± 17.6 kg for the
LCKD group, and from 105.2 ± 19.8 to 98.3 ± 20.3 kg for
the LGID group (Table 2). Both groups had reductions in
systolic blood pressure and diastolic blood pressure
(Table 4).
Other metabolic effects
For fasting lipid profiles, the LCKD group had an increase
in HDL cholesterol (+12.7%), while the LGID group had
no change over the 24 weeks. All 7 parameters associated
Table 1: Baseline participant characteristics*
Characteristic Low -glycemic, reduced-calorie diet Low-carbohydrate, ketogenic diet
Enrollees
(n = 46)
Completers
(n = 29)
Non-completers
(n = 17)
Enrollees
(n = 38)
Completers
(n = 21)
Non-completers
(n = 17)
Age, years 51.8 ± 7.8 50.0 ± 8.4 54.9 ± 5.7 51.8 ± 7.3 51.2 ± 6.1 52.4 ± 8.7
Female gender, % 80.4 79.3 82.3 76.3 66.7 88.2
White race, % 45.7 44.8 47.1 57.9 66.7 47.1
African-American race, % 50 51.7 47.1 36.8 23.8 52.9
College degree, % 58.7 68.9 41.2 57.9 61.9 52.9
Body weight, kg 106.3 ± 20.1 105.2 ± 19.8 108.1 ± 20.9 105.5 ± 19.5 108.4 ± 20.5 101.9 ± 18.1
Body mass index, kg/m2 38.5 ± 5.6 37.9 ± 6.0 39.4 ± 5.0 37.7 ± 6.1 37.8 ± 6.7 37.6 ± 5.3
* Values with plus/minus signs are means ± SD.Nutrition & Metabolism 2008, 5:36 http://www.nutritionandmetabolism.com/content/5/1/36
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with the metabolic syndrome showed improvement for
the LCKD group; 5 of 7 improved for the LGID group
(Table 4).
In terms of renal function, serum creatinine and calcu-
lated GFR did not change significantly over the 24 weeks
for either group. There was a greater reduction in 24-hour
urine protein for the LCKD group (baseline = 445 ± 1175
mg/24 hour, week 24 = 296 ± 750 mg/24 hours, n = 18),
as compared with the LGID group (baseline = 276 ± 705
mg/24 hour, week 24 = 223 ± 623 mg/24 hours, n = 24, p
= 0.007 for between-groups comparison).
Adverse effects
There were no statistically significant differences between
groups in reported symptomatic adverse effects. The most
common symptoms experienced at any point during the
study were headache (LCKD: 53.1%, LGID: 46.3%), con-
Table 2: Effect of diet programs on indices of glycemic control and body weight
Week 0 Week 12 Week 24 Week 0 to 24 Between Groups Between Groups Adjusted*
mean ± sd mean ± sd mean ± sd mean change p value p value
LGID n = 29 n = 29 n = 29
Hemoglobin A1c, % 8.3 ± 1.9 7.5 ± 1.7 7.8 ± 2.1 -0.5 0.03 0.06
Fasting glucose, mg/dL 166.8 ± 63.7 140.7 ± 39.9 150.8 ± 47.4 -16.0** 0.67 0.76
Fasting insulin, μU/mL 14.8 ± 6.9 13.9 ± 9.9 12.6 ± 6.5 -2.2** 0.10 0.84
Body mass index, kg/m2 37.9 ± 6.0 36.5 ± 5.7 35.2 ± 6.1 -2.7** 0.05 0.10
Body weight, kg 105.2 ± 19.8 101.0 ± 16.9 98.3 ± 20.3 -6.9** 0.008 0.01
LCKD n = 21 n = 21 n = 21
Hemoglobin A1c, % 8.8 ± 1.8 7.2 ± 1.2 7.3 ± 1.5 -1.5**
Fasting glucose, mg/dL 178.1 ± 72.9 156.4 ± 50.7 158.2 ± 50.0 -19.9**
Fasting insulin, uU/mL 20.4 ± 9.3 14.3 ± 8.3 14.4 ± 6.9 -6.0**
Body mass index, kg/m2 37.8 ± 6.7 34.4 ± 5.6 33.9 ± 5.8 -3.9**
Body weight, kg 108.4 ± 20.5 100.1 ± 17.8 97.3 ± 17.6 -11.1**
LGID = low-glycemic, reduced-calorie diet; LCKD = low-carbohydrate, ketogenic diet
* Adjusted for baseline values.
** p < 0.05 for within-group change from Baseline to Week 24.
Payoff matrix for dietary comparisons Figure 1
Payoff matrix for dietary comparisons. Matrices show the theoretical paired comparison between the change in hemo-
globin A1c for each individual in the LGI group compared with each individual in the LCKD group. In rank order across the top 
of the matrix, the change in hemoglobin A1c from baseline to week 24 is shown for the LCKD group; down the matrix side is 
shown the LGI group. Each matrix element shows the difference between the value for the LGI (row) and the LCKD (column) 
individual (LGI-LCKD). Positive values indicate greater reduction in hemoglobin A1c for LCKD, negative values indicate greater 
reduction in hemoglobin A1c for LGI. At the right of the Figure, the number of matrix elements in each category are divided by 
the total number of matrix elements (paired differences). LGI = Low glycemic index group, LCKD = Low carbohydrate 
ketogenic diet group, Prob = Probability.
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stipation (LCKD: 53.1%, LGID: 39.0%), diarrhea (LCKD:
40.6%, LGID: 36.6%), insomnia (LCKD: 31.2%, LGID:
19.5%), and back pain (LCKD: 34.4%, LGID: 39.0%) (p >
0.05 for all comparisons).
Discussion
In this study, both a low-glycemic index, reduced-calorie
diet and a low-carbohydrate, ketogenic diet led to
improvement in glycemic control, diabetic medication
elimination/reduction, and weight loss in adherent over-
weight and obese individuals with type 2 diabetes over a
24-week period. The diet containing fewer carbohydrates,
the LCKD, was most effective for improving glycemic con-
trol. In patients taking insulin, the effects were often quite
powerful. For example, participants taking from 40 to 90
units of insulin before the study were able to eliminate
their insulin use, while also improving glycemic control.
Because this effect occurs immediately upon implement-
ing the dietary changes, individuals with type 2 diabetes
who are unable to adjust their own medication or self-
monitor their blood glucose should not make these die-
tary changes unless under close medical supervision.
A low-carbohydrate, ketogenic diet combines two
approaches that, on their own, improve blood glucose
control: weight loss and a reduced-glycemic index diet.
Weight loss via dietary modification has a beneficial effect
Relationship between change in hemoglobin A1c and change  in weight Figure 2
Relationship between change in hemoglobin A1c and 
change in weight. This figure plots the change in hemo-
globin A1c vs. the change in weight from baseline to week 24 
for each individual (r = 0.09425, p = 0.5150). The LCKD 
group is shown as triangles; the LGID group is shown as 
squares.
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Table 3: Changes in medication among patients taking insulin at baseline
Participant Week 0: Total daily dose Week 24: Total daily dose
Low-glycemic, reduced-calorie diet group (total n = 29)
1 insulin 24 units none
insulin sliding scale three times a day none
2 insulin 85 units insulin 13 units
3 insulin 160 units insulin 120 units
Low-carbohydrate, ketogenic diet group (total n = 21)
1 insulin 50 units none
2 insulin 90 units none
3 insulin 32 units none
rosiglitizone 4 mg/metformin 2000 mg metformin 1000 mg
4 insulin 40 units none
metformin 2000 mg metformin 2000 mg
5 insulin 40 units insulin 35 units
insulin sliding scale three times a day none
6 insulin 120 units insulin 90 units
metformin 2000 mg metformin 2000 mg
7 insulin 135 units insulin 60 units
8 insulin 80 units insulin 8 units
pioglitazone 45 mg pioglitazone 45 mg
glimiperide 8 mg glimiperide 8 mg
*Medications were adjusted using a pre-specified algorithm based upon home and return visit blood capillary glucose measurements.Nutrition & Metabolism 2008, 5:36 http://www.nutritionandmetabolism.com/content/5/1/36
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on diabetes [27,28]. A reduced-glycemic index diet with-
out weight loss can also lead to improvement in diabetic
control, with the magnitude of effect of a 0.43% reduction
in hemoglobin A1c, when compared with higher-glycemic
diets of similar carbohydrate content [4]. The greater effect
of the low-carbohydrate, ketogenic diet in this study
appeared to be due to the lower carbohydrate intake,
because statistical significance remained after adjustment
for weight loss. Because "low-glycemic" diets in previous
studies typically contain from 40–60% of calories from
carbohydrate, it is possible that the beneficial effect of
"low-glycemic" diets could be augmented by further
reduction of the absolute amount of carbohydrate, or by
a reduction in caloric content.
While this study was a treatment trial of individuals with
type 2 diabetes, lifestyle modification has been shown to
prevent type 2 diabetes in the Diabetes Prevention Pro-
gram (DPP). The intensive lifestyle modification arm of
the DPP included a calorie- and fat-restricted diet with an
energy intake of 1380 kcal/day for women and 1583 kcal/
day for men, and a percentage of energy from carbohy-
drate of 54% [29]. While the effect was stronger than med-
ication, the intensive lifestyle group developed diabetes at
a rate of 20% after 4 years. Future research should include
the use of lower-carbohydrate diets for the treatment and
prevention of type 2 diabetes.
Like previous studies, we found that the LCKD led to
weight reduction, improvement in glycemic control, and
elevation in HDL-cholesterol, but no deterioration in fast-
ing lipid parameters. Extending these findings, we
observed that all metabolic syndrome components were
improved by the LCKD [30]. It is interesting to note that
the LGID group reported consuming fewer calories than
the LCKD group, yet had less weight loss. This may reflect
problems with the diet data as collected, issues with differ-
ential physical activity, or metabolic inefficiency (leading
to increased energy expenditure) which may occur during
the consumption of a carbohydrate-restricted diet.
Limitations of this study include the lack of blinding of
physicians and outcome assessors to treatment group, and
the use of food records. The study participants were com-
munity volunteers, and predominantly women, which
may limit generalization of these findings to clinical pop-
ulations and men. The analysis and presentation of only
detailed food records may bias the estimate of food
intake. We chose the "completer analysis" as the primary
outcome because we were interested in answering the
question of what might be expected from patients who
can adhere to the intervention. The LOCF analysis might
generalize better to a population of patients who have dif-
ferent food preferences from their assigned diet, who lose/
lack motivation, or who experience other barriers to die-
tary change. Another possible limitation is the baseline
imbalance in the primary outcome, HgA1c, which
Table 4: Effect of diet programs on metabolic syndrome parameters and fasting lipid profiles
Low glycemic, reduced-calorie diet group (n = 29) Low carbohydrate, ketogenic diet group (n = 21)
Test Week 0 Week 24 Week 0 to 24 Week 0 Week 24 Week 0 to 24
mean ± sd mean ± sd mean change mean ± sd mean ± sd mean change
Fasting glucose, mg/dL 166.8 ± 63.7 150.8 ± 47.4 -16.0 * 178.1 ± 72.9 158.2 ± 50.0 -19.9*
Waist circumference, inches 47.0 ± 5.1 42.4 ± 5.5 -4.6 * 47.1 ± 5.5 41.8 ± 5.3 -5.3 *
Triglycerides, mg/dL 167.1 ± 125.7 147.8 ± 128.5 -19.3 210.4 ± 10.3 142.9 ± 76.9 -67.5 *
HDL cholesterol, mg/dL 48.7 ± 11.8 48.7 ± 10.1 -0 † 44.0 ± 8.7 49.6 ± 11.7 +5.6 * †
Systolic blood pressure, mmHg 140.8 ± 15.7 130.1 ± 17.1 -10.7 * 144.4 ± 15.0 127.8 ± 13.4 -16.6 *
Diastolic blood pressure, mmHg 84.1 ± 11.0 78.5 ± 8.7 -5.6 * 83.9 ± 10.3 75.8 ± 10.9 -8.1 *
Body mass index, kg/m2 37.9 ± 6.0 35.2 ± 6.1 -2.7 * † 37.8 ± 6.7 33.9 ± 5.8 -3.9 * †
Total cholesterol, mg/dL 190.6 ± 43.8 184.8 ± 45.6 -5.8 191.4 ± 32.0 187.0 ± 35.8 -4.4
LDL cholesterol, mg/dL 113.8 ± 40.9 111.0 ± 42.2 -2.8 105.8 ± 25.7 107.1 ± 26.3 +1.3
VLDL cholesterol, mg/dL 27.7 ± 13.2 24.4 ± 12.3 -3.3* 37.3 ± 14.9 27.3 ± 15.2 -10.0*
Total cholesterol/HDL cholesterol ratio 4.1 ± 1.3 3.9 ± 1.2 -0.2 4.5 ± 1.1 4.1 ± 4.1 -0.4
Triglyceride/HDL cholesterol ratio 3.9 ± 3.7 3.3 ± 3.1 -0.6 5.2 ± 3.4 3.4 ± 3.0 -1.8*
These changes were observed with a reduction or elimination of diabetic medication as shown in Table 3.
HDL = high-density lipoprotein; LDL = low-density lipoprotein; VLDL = very-low-density lipoprotein
* p < 0.05 for within-group change from Baseline to Week 24.
† p < 0.05, for between-groups comparison of changes from Baseline to Week 24.
P values with adjustment for baseline values: fasting glucose: 0.76, waist circumference: 0.43, triglycerides: 0.17, HDL: 0.09, systolic blood pressure: 
0.89, diastolic blood pressure: 0.48, body mass index: 0.10, total cholesterol: 0.85, LDL: 0.79, VLDL: 0.24, total cholesterol/HDL ratio: 0.92, 
triglyceride/HDL ratio: 0.54.Nutrition & Metabolism 2008, 5:36 http://www.nutritionandmetabolism.com/content/5/1/36
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occurred despite random allocation. The equation used to
calculate energy requirements for the LGID participants
may underestimate requirements, particularly in obese
people. This would result in more severe energy restriction
than the 500 kcal deficit as stated, which might bias the
weight loss effects in favor of the LGID.
It is often presumed that obesity is the cause of type 2 dia-
betes, but there are clearly instances where obesity occurs
without type 2 diabetes, and instances where type 2 diabe-
tes occurs without obesity. In this study, the change in
hemoglobin A1c was independent of the change in weight
(Figure 2). This supports the concept that weight change
and glycemic control are not serially linked but rather may
be the result of the same pathophysiologic process, such
as abnormal insulin metabolism.
The underlying principle of carbohydrate-restriction and
the historic precedents of using the low-carbohydrate diet
for type 2 diabetes suggest that the low-carbohydrate
approach may be one of the most effective dietary treat-
ments for diabetes. Our findings support this position,
and it suggests that the burden of proof be placed upon
alternative points of view. The dearth of randomized, con-
trolled trials using the low-carbohydrate approach for
type 2 diabetes, despite the historical and current clinical
use of these approaches, challenges the idea that the ran-
domized controlled trial should be the only guide of sci-
entific inquiry and clinical practice.
Conclusion
In summary, lifestyle modification using two diets that
reduce carbohydrate intake led to improvement in glyc-
emic control, diabetic medication elimination/reduction,
and weight loss in overweight and obese individuals with
type 2 diabetes over a 24-week period in the outpatient
setting. The diet containing fewer carbohydrates, the low-
carbohydrate, ketogenic diet, was more effective for
improving glycemic control than the low glycemic diet.
Lifestyle modification using low-carbohydrate diet inter-
ventions are effective for improving obesity and type 2
diabetes, and may play an important role in reversing the
current epidemic of 'diabesity.'
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